Introduction: Many people with T1D experience an early-morning rise in glucose (i.e., dawn phenomenon, DP). The MM670G/770G with 5-min auto basal insulin reduced the burden of managing DP.1 With MM780G frequent (every 5-min) autocorrections, we hypothesized that DP hyperglycemia would be reduced further. In this analysis, the impact of the MM780G against real-world DP in adolescents and adults with T1D was evaluated.

Methods: Prevalence of DP was defined as an elevation (>20mg/dL) in sensor glucose (SG) from 3AM to 6AM, compared to 12AM to 3AM, at least 30% of nights. DP was assessed among MM780G users (aged ≥16 years) in the U.S. who consented to share data. DP and glycemic outcomes (mean glucose, time in ranges and insulin delivery) were assessed in 6026 overall users and 1303 who used recommended settings (RS, a glucose target of 100mg/dL with active insulin time of 2 hours for 95% of the time).

Results: Transition from the MM770G to the MM780G decreased DP rates from 12.2% to 4.5% in all users, and to 3.0% in RS users. Glycemic outcomes were significantly improved with the MM780G (Table), consistent with the trend observed in DP rates. The % of total insulin delivered as auto bolus from 3AM to 6AM was 10.6% and 11.3% for use of all settings and RS, respectively.

Conclusion: Hyperglycemia from real-world DP was nearly eliminated by the MM780G system due to the ability of its algorithm to autocorrect frequently overnight.

graphic
View largeDownload slide
Disclosure

J. McVean: Employee; Medtronic. J. Shin: None. F. Niu: None. F. Diaz-Garelli: Employee; Medtronic. R.A. Vigersky: Employee; Medtronic.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.